ERLI PLUS 12.5/850MG TAB

Generic Name: Empagliflozin

Therapeutic Segment: Anti-diabetic

Indication:

• Glycemic control in Diabetes Mellitus Type II, risk of cardiovascular death in adult patient with Diabetes Mellitus Type II.

Available as: Tablets

DESCRIPTION

Empagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, lowers the renal threshold for glucose and increases urinary glucose excretion by interfering with the reabsorption of renally-filtered glucose across the tubular lumen of the proximal renal tubules. Empagliflozin decreases fasting and post-prandial blood glucose levels, and imparts a low risk of hypoglycemia as its mechanism of action is independent of beta cell function and insulin pathway

INSTRUCTIONS Use as advised by the physician. Keep all medicines out of the reach of children. To be sold on the prescription of a registered medical practitioner only. Protect from light, heat and moisture. Store below 30°C.